Literature DB >> 24035674

Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down?

Manzoor A Rather1, Bilal A Bhat, Mushtaq A Qurishi.   

Abstract

Natural product based drugs constitute a substantial proportion of the pharmaceutical market particularly in the therapeutic areas of infectious diseases and oncology. The primary focus of any drug development program so far has been to design selective ligands (drugs) that act on single selective disease targets to obtain highly efficacious and safe drugs with minimal side effects. Although this approach has been successful for many diseases, yet there is a significant decline in the number of new drug candidates being introduced into clinical practice over the past few decades. This serious innovation deficit that the pharmaceutical industries are facing is due primarily to the post-marketing failures of blockbuster drugs. Many analysts believe that the current capital-intensive model-"the one drug to fit all" approach will be unsustainable in future and that a new "less investment, more drugs" model is necessary for further scientific growth. It is now well established that many diseases are multi-factorial in nature and that cellular pathways operate more like webs than highways. There are often multiple ways or alternate routes that may be switched on in response to the inhibition of a specific target. This gives rise to the resistant cells or resistant organisms under the specific pressure of a targeted agent, resulting in drug resistance and clinical failure of the drug. Drugs designed to act against individual molecular targets cannot usually combat multifactorial diseases like cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory diseases. Combination drugs that affect multiple targets simultaneously are better at controlling complex disease systems and are less prone to drug resistance. This multicomponent therapy forms the basis of phytotherapy or phytomedicine where the holistic therapeutic effect arises as a result of complex positive (synergistic) or negative (antagonistic) interactions between different components of a cocktail. In this approach, multicomponent therapy is considered to be advantageous for multifactorial diseases, instead of a "magic bullet" the metaphor of a "herbal shotgun" might better explain the state of affairs. The different interactions between various components might involve the protection of an active substance from decomposition by enzymes, modification of transport across membranes of cells or organelles, evasion of multidrug resistance mechanisms among others.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Blockbuster drugs; Combination therapy; Drug development; Phytotherapy; Synergism

Mesh:

Substances:

Year:  2013        PMID: 24035674     DOI: 10.1016/j.phymed.2013.07.015

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  25 in total

1.  Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Chanyuan Li; Guangping Zhang; Wu Huan; Fei Wu
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

2.  Cognitive assessment of pycnogenol therapy following traumatic brain injury.

Authors:  Stephen W Scheff; Kelly N Roberts
Journal:  Neurosci Lett       Date:  2016-10-11       Impact factor: 3.046

3.  Peripheral and central antinociceptive effects of the butanolic fraction of Byrsonima verbascifolia leaves on nociception-induced models in mice.

Authors:  A A Saldanha; J M Siqueira; A H F Castro; N A Matos; A Klein; D B Silva; C A Carollo; A C Soares
Journal:  Inflammopharmacology       Date:  2016-12-20       Impact factor: 4.473

Review 4.  Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2.

Authors:  Lindsay K Caesar; Nadja B Cech
Journal:  Nat Prod Rep       Date:  2019-06-19       Impact factor: 13.423

Review 5.  Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.

Authors:  Harbinder Singh; Devendra K Agrawal
Journal:  Bioorg Med Chem       Date:  2022-03-11       Impact factor: 3.461

6.  Botanical Integrity: Part 2: Traditional and Modern Analytical Approaches.

Authors:  Charlotte Simmler; Shao-Nong Chen; Jeff Anderson; David C Lankin; Rasika Phansalkar; Elizabeth Krause; Birgit Dietz; Judy L Bolton; Dejan Nikolic; Richard B van Breemen; Guido F Pauli
Journal:  HerbalGram       Date:  2016

7.  Anti-proliferative and apoptotic activities of constituents of chloroform extract of Juglans regia leaves.

Authors:  M Salimi; M H Ardestaniyan; H Mostafapour Kandelous; S Saeidnia; A R Gohari; A Amanzadeh; H Sanati; Z Sepahdar; S Ghorbani; M Salimi
Journal:  Cell Prolif       Date:  2014-01-27       Impact factor: 6.831

Review 8.  Molecular targets of naturopathy in cancer research: bridge to modern medicine.

Authors:  Aamir Ahmad; Kevin R Ginnebaugh; Yiwei Li; Subhash B Padhye; Fazlul H Sarkar
Journal:  Nutrients       Date:  2015-01-06       Impact factor: 5.717

9.  A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines.

Authors:  Fang Long; Hua Yang; Yanmin Xu; Haiping Hao; Ping Li
Journal:  Sci Rep       Date:  2015-07-22       Impact factor: 4.379

10.  A New Drug Combinatory Effect Prediction Algorithm on the Cancer Cell Based on Gene Expression and Dose-Response Curve.

Authors:  C Pankaj Goswami; L Cheng; P S Alexander; A Singal; L Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.